Lipase production inhibitors, agents for preventing and / or improving problems caused by lipase, cosmetics, pharmaceuticals, quasi-drugs, or food and beverages, and methods for inhibiting lipase production.

Abstract

To provide a novel technology for suppressing lipase production by lipase-producing bacteria. [Solution] A lipase production inhibitor is provided, which contains an extract of edelweiss (Leontopodium alpinum) as an active ingredient, to suppress lipase production by lipase-producing bacteria. A lipase production inhibitor is provided, which contains an extract of edelweiss (Leontopodium alpinum) as an active ingredient, to prevent and / or improve problems caused by lipase. A lipase production inhibitory method is provided, which includes the step of applying and / or ingesting an extract of edelweiss (Leontopodium alpinum) to suppress lipase production by lipase-producing bacteria.

Description

Technical Field

[0001] The present technology relates to a lipase production inhibitor. More specifically, it relates to a lipase production inhibitor, an agent for preventing and / or improving troubles caused by lipase, a cosmetic, a pharmaceutical product, a quasi-drug, or a food or drink, and a method for inhibiting lipase production.

Background Art

[0002] Lipase-producing bacteria that produce lipase produce bacterial lipase and decompose and utilize lipids. Free fatty acids, which are decomposition products of bacterial lipase, are the cause of various troubles. For example, acne bacteria and Staphylococcus epidermidis, which are lipase-producing bacteria, produce lipase and decompose and utilize sebum, but free fatty acids, which are decomposition products of lipase, are the cause of skin troubles such as skin inflammation, acne, and grinding bowl pores.

[0003] Under such a background, technologies for inhibiting lipase activity are being developed. For example, Patent Document 1 discloses a lipase activity inhibitor that uses a propylene glycol extract of hibiscus and has a highly safe and remarkable lipase activity inhibitory effect.

[0004] Also, for example, Patent Document 2 discloses a lipase inhibitor, a lipid absorption inhibitor, an anti-obesity agent, a hyperlipidemia improving agent, a skin improving agent for acne, a cosmetic, and a food or drink that use a specific plant having a lipase inhibitory action as an active ingredient.

[0005] Furthermore, for example, Patent Document 3 discloses that the extract of Simonilo has a lipase inhibitory action, and by further blending specific drugs (humectants, cell activators, anti-inflammatory agents, antioxidants, whitening agents, anti-plasmin agents, active oxygen inhibitors, antihistamines, etc.), it is possible to improve various skin problems such as wrinkles, dullness, and rough skin.

Prior Art Documents

Patent Documents

[0006] [Patent Document 1] Japanese Patent Publication No. 2010-43008 [Patent Document 2] Japanese Patent Publication No. 2005-8572 [Patent Document 3] Japanese Patent Publication No. 2006-219448 [Overview of the Initiative] [Problems that the invention aims to solve]

[0007] As mentioned above, many technologies have been proposed to inhibit lipase activity, but the technologies described in Patent Documents 1 to 3 suppress the activity of lipase that has already been produced. On the other hand, if it were possible to suppress the lipase production stage from lipase-producing bacteria, it could contribute to further purposes and applications.

[0008] Therefore, the primary objective of this technology is to provide a novel technique for suppressing lipase production by lipase-producing bacteria. [Means for solving the problem]

[0009] The inventors of this application diligently searched for a substance that inhibits lipase production by lipase-producing bacteria, and discovered that an extract of edelweiss (Leontopodium alpinum) has a high lipase production inhibitory effect, thus completing this technology.

[0010] In other words, this technology first provides a lipase production inhibitor that contains an extract of edelweiss (Leontopodium alpinum) as an active ingredient, which suppresses lipase production by lipase-producing bacteria. The lipase-producing bacteria that can suppress lipase production with the lipase production inhibitor related to this technology may be commensal skin bacteria. As a skin flora, *Propionibacterium acnes* would also be acceptable. The lipase production inhibitor related to this technology may maintain the survival rate of the lipase-producing bacteria at 60% or higher.

[0011] This technology then provides an agent for preventing and / or improving lipase-related problems, which contains an extract of edelweiss (Leontopodium alpinum) as an active ingredient. The problems that the preventive and / or corrective agents related to this technology can prevent and / or improve may include skin problems. Acne is a valid example of a skin problem.

[0012] This technology further provides cosmetics, pharmaceuticals, quasi-drugs, or food and beverages containing a lipase production inhibitor related to this technology, or a preventive and / or ameliorative agent related to this technology.

[0013] This technology also provides a method for inhibiting lipase production by lipase-producing bacteria, which further includes the step of applying and / or ingesting an extract of edelweiss (Leontopodium alpinum). [Modes for carrying out the invention]

[0014] The following describes preferred embodiments for implementing this technology. The embodiments described below represent typical embodiments of this technology, and the scope of this technology is not limited to these embodiments.

[0015] 1. Lipase production inhibitors, and agents for preventing and / or improving problems caused by lipase. The lipase production inhibitor and the preventive and / or corrective agent for lipase-related problems related to this technology contain an extract of edelweiss (Leontopodium alpinum) as the active ingredient.

[0016] (1) Edelweiss extract Edelweiss is an alpine plant belonging to the genus Leontopodium in the family Asteraceae. Its scientific name is Leontopodium alpinum, and its Japanese name is Seiyo-usuyukisou (Western Edelweiss). Edelweiss extract is obtained by extracting one or more parts selected from the roots, stems, leaves, flowers, fruits, etc., of the edelweiss plant with a suitable solvent. Typically, a concentrated solution of the extracted solvent is used. Freeze-dried versions of this concentrated solution can also be used in this technology.

[0017] The specific part of the edelweiss used for extraction is not particularly limited as long as it does not impair the purpose of this technology, but it is preferable to select the whole plant, including all parts such as roots, stems, leaves, flowers, and fruits, and it is more preferable to select the above-ground parts such as stems, leaves, flowers, and fruits. Furthermore, the extraction part may be used immediately after harvesting, or it may be dried before extraction. If necessary, it may also be processed by crushing, cutting, shredding, shaping, etc., before use for extraction.

[0018] The solvent used for extraction is not particularly limited, and one or more solvents that can normally be used for plant extraction can be freely selected and used. Examples include water, alcohols, glycols, ketones, esters, ethers, carbon halides, supercritical solvents (such as carbon dioxide), and subcritical solvents. Examples of alcohols include ethanol, methanol, and propanol. Examples of glycols include ethylene glycol, diethylene glycol, butylene glycol, and propylene glycol. Examples of ketones include acetone and methyl ethyl ketone. Examples of esters include ethyl acetate, propyl acetate, and ethyl formate. These solvents may be used individually or as aqueous solutions, or as a mixture of any two or three or more solvents. In this technology, the use of alcohols is particularly preferred, and among alcohols, the use of ethanol is more preferred.

[0019] The extraction method is not particularly limited, and usually, the extraction method used in plant extraction can be freely selected and used. For example, after any part of edelweiss is pulverized, cut, shredded, etc. as necessary, it is immersed in the solvent for a predetermined time and then filtered; or after extraction is performed while heating and stirring at a temperature below the boiling point of the solvent, followed by filtration. Also, it is possible to combine methods such as concentrating the filtrate or removing the solvent from the filtrate before and after concentration.

[0020] The extract of edelweiss can be used as it is as an active ingredient of the lipase production inhibitor according to the present technology and the preventive and / or improvement agent for troubles caused by lipase. However, it is also possible to further fractionate a highly active fraction from the extract by appropriate separation means (for example, partition extraction, gel filtration method, silica gel chromatography method, reverse-phase or normal-phase high-performance liquid chromatography method, etc.) and use it.

[0021] The dry solid content concentration of the extract of edelweiss used in the lipase production inhibitor according to the present technology and the preventive and / or improvement agent for troubles caused by lipase can be freely set according to the type of extraction solvent, extraction method, etc., as long as the effects of the present technology are not impaired.

[0022] In the present technology, in particular, the lower limit value of the dry solid content concentration of the extract of edelweiss can be, for example, 0.01% by mass or more, preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and still more preferably 0.2% by mass or more. By setting the lower limit value of the dry solid content concentration within this range, a higher lipase production inhibitory effect and preventive and / or improvement effects for troubles can be exerted.

[0023] Also, the upper limit value of the dry solid content concentration of the extract of edelweiss can be, for example, 10% by mass or less, preferably 5% by mass or less, more preferably 2% by mass or less, and still more preferably 1% by mass or less. By setting the upper limit value of the dry solid content concentration within this range, the generation of odor and precipitation derived from plants can be prevented, and it can also contribute to cost reduction.

[0024] (2) Other ingredients The lipase production inhibitor and the preventive and / or corrective agent for lipase-related problems related to this technology may contain, as long as they do not impair the effectiveness of this technology, one or more other ingredients that can be freely selected and used in the fields of cosmetics, food and beverages, pharmaceuticals and quasi-drugs. For example, ingredients such as preservatives, emulsifiers, pH adjusters, colorants, antiseptics, and surfactants can be used.

[0025] (3) Lipase-producing bacteria The lipase production inhibitor related to this technology can be applied to any lipase-producing bacteria that can produce lipase, as long as the bacteria are capable of producing lipase.

[0026] Examples of lipase-producing bacteria include commensal skin bacteria. Examples of commensal skin bacteria include *Cutibacterium acnes* (including the bacteria formerly known as *Propionibacterium acnes*) and *Staphylococcus epidermidis*.

[0027] Skin problems arise when the balance of commensal skin bacteria is disrupted. For example, Propionibacterium acnes, which is considered a cause of acne, can cause inflammation if it proliferates excessively. On the other hand, it plays a role in maintaining the skin surface at a slightly acidic pH by producing propionic acid and fatty acids using sebum as food, thereby suppressing the growth of highly pathogenic bacteria that adhere to the skin. Similarly, Staphylococcus epidermidis plays a role in preventing the proliferation of Staphylococcus aureus by maintaining the skin at a slightly acidic pH and producing antimicrobial peptides. In addition, the glycerin produced by Staphylococcus epidermidis plays a role in maintaining the skin's barrier function.

[0028] The lipase production inhibitor and the preventive and / or corrective agent for lipase-related problems related to this technology can suppress only lipase production without sterilizing or killing the commensal skin bacteria. Therefore, by using the lipase production inhibitor and the preventive and / or corrective agent for lipase-related problems related to this technology, it is possible to suppress lipase production by lipase-producing bacteria without disrupting the balance of the skin microbiota.

[0029] Specifically, the lipase production inhibitor and the preventive and / or corrective agent for lipase-related problems according to this technology can maintain the survival rate of lipase-producing bacteria at 60% or higher. The survival rate of lipase-producing bacteria when using the lipase production inhibitor and the preventive and / or corrective agent for lipase-related problems according to this technology is preferably 70% or higher, more preferably 80% or higher, and even more preferably 90% or higher.

[0030] (4) Problems caused by lipase The lipase-related preventive and / or corrective agent for lipase-related problems can be applied to any problem that is caused by lipase.

[0031] Problems caused by lipase include, for example, skin problems. These skin problems include acne, redness, inflammation, rough skin, and enlarged pores.

[0032] 2. Cosmetics The lipase production inhibitor and the preventive and / or corrective agent for lipase-related problems related to this technology can be suitably used in all forms of cosmetics by utilizing their excellent lipase production inhibitory effect and their ability to prevent and / or correct problems. For example, it can be applied to skincare cosmetics such as lotions, emulsions, creams, serums, and face masks; makeup cosmetics such as foundations, concealers, makeup bases, lipsticks, blushes, eyeshadows, and eyeliners; and sunscreens. Examples of cosmetic formulations include water-based, oil-based, soluble, and emulsion types (O / W type, W / O type, W / O / W type, O / W / O type).

[0033] In addition to the lipase production inhibitor and the agent for preventing and / or improving problems caused by lipase, the cosmetic composition relating to this technology may contain one or more ingredients that can be freely selected and used in ordinary cosmetic compositions. For example, it may contain all additives that can be commonly used in the field of cosmetics, such as base materials, preservatives, emulsifiers, colorants, antiseptics, surfactants, UV absorbers, antioxidants, humectants, fragrances, antifungal agents, extender pigments, coloring pigments, alcohol, and water.

[0034] Furthermore, because the lipase production inhibitor and the preventive and / or corrective agent for lipase-related problems related to this technology are derived from natural ingredients, there is little need to be careful when using them in combination with other active ingredients. Therefore, in addition to the lipase production inhibitor and the preventive and / or corrective agent for lipase-related problems related to this technology, other active ingredients can be freely added to cosmetics related to this technology as needed.

[0035] In the cosmetic composition relating to this technology, the content of lipase production inhibitors and lipase-related trouble prevention and / or improvement agents is not particularly limited and can be freely set according to the purpose. In this technology, the lower limit of the dry solid content of edelweiss extract in the cosmetic composition can be, for example, 0.01% by mass or more, preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and even more preferably 0.2% by mass or more. By setting the lower limit of the dry solid content concentration within this range, a higher lipase production inhibitory effect and trouble prevention and / or improvement effect can be achieved.

[0036] Furthermore, the upper limit of the dry solid content of edelweiss extract in the cosmetic composition can be, for example, 10% by mass or less, preferably 5% by mass or less, more preferably 2% by mass or less, and even more preferably 1% by mass or less. By setting the upper limit of the dry solid content concentration within this range, it is possible to prevent the generation of plant-derived odors and precipitates, and also contribute to cost reduction.

[0037] Cosmetics using the cosmetic formulation related to this technology, as described above, are highly safe and can be used continuously for extended periods because their active ingredients are derived from natural sources.

[0038] 3. Pharmaceuticals, quasi-drugs, and food and beverages. The lipase production inhibitor and the preventive and / or ameliorative agent for lipase-related problems related to this technology can be suitably used in pharmaceuticals, quasi-drugs, and food and beverages by utilizing their excellent lipase production inhibitory effect and their effect in preventing and / or ameliorating problems. Pharmaceuticals and quasi-drugs can be formulated into any desired dosage form depending on the method of administration, such as oral or parenteral administration, and the dosage form is not particularly limited. For oral administration of pharmaceuticals, for example, they can be formulated into solid preparations such as powders, granules, tablets, lozenges, and capsules; and liquid preparations such as solutions, syrups, suspensions, and emulsions. For parenteral administration, for example, they can be formulated into topical skin preparations, suppositories, vaginal tablets, inhalants, nasal sprays, and injections. For quasi-drugs, for example, they can be formulated into powders, granules, tablets, lozenges, capsules, liquid preparations, syrups, topical skin preparations, ointments, and aerosols. With regard to pharmaceuticals and quasi-drugs, this technology particularly favors formulation into topical skin preparations. Examples of topical skin preparations include topical liquids, topical gels, creams, ointments, sprays, liniments, lotions, poultices, plasters, sprays, aerosols, and patches. Food and beverages can take any form, including frozen foods and beverages, powders, sheets, bottles, cans, retort pouches, capsules, tablets, and processed forms such as natural liquid foods, semi-digested nutritional foods, elemental nutritional foods, and drinks containing proteins, sugars, fats, trace elements, vitamins, emulsifiers, and flavorings. The types of food and beverages are not particularly limited and include, for example, candies, chewing gum, and beverages.

[0039] Pharmaceuticals, quasi-drugs, and food and beverages relating to this technology may contain one or more pharmacologically acceptable additives, which can be freely selected. For example, when pharmaceuticals and quasi-drugs relating to this technology are applied to topical skin preparations, they may contain all additives that are commonly used in the field of pharmaceutical and quasi-drug formulations, such as bases, surfactants, preservatives, emulsifiers, colorants, deodorizers, fragrances, stabilizers, antiseptics, antioxidants, lubricants, solubilizers, and suspending agents.

[0040] The lipase production inhibitors and lipase-related preventive and / or corrective agents related to this technology have naturally derived active ingredients, thus requiring little caution when used in combination with other drugs. Therefore, it is possible to freely select one or more existing drugs to create combination agents. For example, any drug such as antibacterial agents, anti-inflammatory analgesics, steroids, antifungal agents, cough suppressants, antihistamines, vitamins, and antitumor agents can be combined. Furthermore, ingredients that have preventive, corrective, and / or therapeutic effects on conventionally known or future-discovered diseases and symptoms can be used in combination as appropriate, as long as they do not impair the effectiveness of this technology.

[0041] In pharmaceuticals, quasi-drugs, and food and beverages relating to this technology, the content of lipase production inhibitors and lipase-related trouble prevention and / or improvement agents is not particularly limited and can be freely set according to the purpose. In this technology, the lower limit of the dry solid content of edelweiss extract in pharmaceuticals, quasi-drugs, and food and beverages can be, for example, 0.01% by mass or more, preferably 0.05% by mass or more, more preferably 0.1% by mass or more, and even more preferably 0.2% by mass or more. By setting the lower limit of the dry solid content concentration within this range, a higher lipase production inhibitory effect and trouble prevention and / or improvement effect can be achieved.

[0042] Furthermore, the upper limit of the dry solid content of edelweiss extract in pharmaceuticals, quasi-drugs, and food and beverages can be, for example, 10% by mass or less, preferably 5% by mass or less, more preferably 2% by mass or less, and even more preferably 1% by mass or less. By setting the upper limit of the dry solid content concentration within this range, it is possible to prevent the generation of plant-derived odors and precipitates, and also contribute to cost reduction.

[0043] The pharmaceuticals, quasi-drugs, and food products related to this technology, as described above, have active ingredients derived from natural sources, making them highly likely to be safe for patients suffering from various diseases. Furthermore, the likelihood of side effects is low even with long-term, continuous administration.

[0044] 4. Methods for inhibiting lipase production The method for inhibiting lipase production related to this technology includes the step of applying and / or ingesting an extract of edelweiss (Leontopodium alpinum).

[0045] The method of administration is not particularly limited, and either oral or parenteral administration can be chosen. Parenteral administration methods include, for example, transdermal, enteral, vaginal, sublingual, oral, inhalation, nasal, intravenous, intra-arterial, intramuscular, intradermal, and subcutaneous administration. Transdermal administration methods include topical application and application of patches containing edelweiss extract. Topical application methods include application with hands or fingers, application with cotton or a brush, and spray application. [Examples]

[0046] The present technology will be described in more detail below based on the following examples. The examples described below are representative examples of the present technology and should not be interpreted as narrowing the scope of the present technology.

[0047] <Experimental Example 1> In Experimental Example 1, the lipase production inhibitory effects of various plant extracts were confirmed.

[0048] (1) Culturing of acne bacteria To 19 mL of Shimadzu Diagnostics Corporation's "AccuDia® Modified GAM Agar Medium," 1 mL of 10% fresh cream solution and the amounts of various plant extracts shown in Table 1 below were added to prepare agar plates in a petri dish. Propionibacterium acnes was spot-inoculated onto the prepared agar plates and incubated under microaerophilic conditions at 36°C for 7 days.

[0049] (2) Measurement and evaluation of the clear zone When lipase is secreted by microorganisms, a clear zone is formed around the colony on the culture medium. Using this, the diameter of the clear zone around the acne bacteria colony and the diameter of the colony were measured, and the clear zone score was calculated using the following formula (1). Clear Zone Score = Clear Zone Diameter / Colony Diameter ... (1)

[0050] Based on the calculated Clear Zone score, the lipase production inhibitory effect was evaluated according to the following evaluation criteria. ◎: Clear Zone Score less than 1.5 ○: Clear Zone Score 1.5 or higher and less than 2.0 ×: Clear Zone score of 2.0 or higher

[0051] (3) Results The results are shown in Table 1 below.

[0052] [Table 1]

[0053] (4) Discussion As shown in Table 1, Examples 1-5, in which *Propionibacterium acnes* was cultured in a medium supplemented with edelweiss extract, showed lower Clear Zone scores compared to Comparative Example 1, in which *Propionibacterium acnes* was cultured in a medium without the supplement, and Comparative Examples 2-7, in which *Propionibacterium acnes* was cultured in a medium supplemented with other plant extracts. In other words, it was confirmed that lipase production by *Propionibacterium acnes* was suppressed in the medium supplemented with edelweiss extract.

[0054] <Examples 6-16> In Examples 6-16, cosmetics, quasi-drugs, and food products containing edelweiss extract were prepared.

[0055] [Example 6: Lotion] The lotion was prepared using the following method. (Manufacturing method) A. The following components (1) to (6) were mixed and dissolved. B. The following components (7) to (11) were mixed and dissolved. B was added to CA and mixed to obtain a lotion.

[0056] (1) Polyoxyethylene glycerin (26 E.O.): 6.0% by mass (2) Glycerin: 3.0% by mass (3) Dipropylene glycol: 3.0% by mass (4) 1,3-Butylene glycol: 17.0% by mass (5) Diglycerin: 1.0% by mass (6) Purified water: remaining amount (7) Edelweiss extract: 0.1% by mass (8) Purified water: 5.0% by mass (9) Fragrance: 0.1% by mass (10) Citric acid: 0.1% by mass (11) Phenoxyethanol: 0.3% by mass

[0057] (result) When this lotion was used by five people for two weeks, the redness of their cheeks was reduced compared to before use. Thus, it was confirmed that cosmetics containing edelweiss extract act on skin resident bacteria such as acne bacteria to suppress lipase production, resulting in reduced sebum breakdown and thus a reduction in skin redness.

[0058] [Example 7: Emulsion] The emulsion was prepared using the following method. (Manufacturing method) A. The following components (1) to (7) were heated and dissolved, and the temperature was maintained at 70°C. B. The following components (8) to (11) were heated and dissolved, and the temperature was maintained at 70°C. CA was emulsified with B, then cooled, and the following component (12) was added and mixed. The following ingredients (13) to (14) were added to DC to neutralize it, and then (15) to (19) were added and mixed uniformly to obtain an emulsion.

[0059] (1) Sucrose fatty acid ester: 0.8% by mass (2) Lipophilic glyceryl monostearate: 0.1% by mass (3) Batyl alcohol: 0.1% by mass (4) Polyethylene glycol monostearate: 0.1% by mass (5) 1,3-Butylene glycol: 1.0% by mass (6) Concentrated glycerin: 3.0% by mass (7) Methylparaben: 0.1% by mass (8) Sorbitan sesquioleate: 0.05% by mass (9) α-olefin oligomer: 4.0% by mass (10) Hydrogenated oil: 0.5% by mass (11) Glyceryl tri-2-ethylhexanoate: 1.5% by mass (12) 1% carboxyvinyl polymer solution: 18.0% by mass (13) Sodium hydroxide: 0.07% by mass (14) Purified water: 7.0% by mass (15) Ethanol: 6.0% by mass (16) 1,3-Butylene glycol: 8.0 remaining (17) Edelweiss extract: 0.15% by mass (18) Disodium edetate: 0.02% by mass (19) Purified water: remaining amount

[0060] (result) When five people used this lotion continuously for two weeks, the redness of their cheeks was reduced compared to before use.

[0061] [Example 8: Cream] The cream was prepared using the following method. (Manufacturing method) A. The following components (1) to (13) were heated and dissolved, and the temperature was maintained at 70°C. B. The following components (14) to (19) were heated and dissolved, and the temperature was maintained at 70°C. CA was emulsified with B, and then the following ingredient (20) was added and mixed to obtain a cream.

[0062] (1) Lipophilic glyceryl monostearate: 2.5% by mass (2) Cetanol: 2.0% by mass (3) Stearic acid: 2.0% by mass (4) Vaseline: 7.0% by mass (5) Methylpolysiloxane: 2.0% by mass (6) Isotridecyl myristate: 5.0% by mass (7) Liquid paraffin: 5.0% by mass (8) Squalane: 5.0% by mass (9) Beeswax: 1.0% by mass (10) Cetyl palmitate: 2.0% by mass (11) Sorbitan sesquioleate: 0.5% by mass (12) Polyoxyethylene (20E.O.) sorbitan monooleate: 1.5% by mass (13) Methylparaben: 0.3% by mass (14) Triethanolamine: 1.2% by mass (15) Dipropylene glycol: 10.0% by mass (16) Glycerin: 3.0% by mass (17) 1,3-Propanediol: 5.0% by mass (18) Edelweiss extract: 0.9% by mass (19) Purified water: remaining amount (20) 1% aqueous solution of xanthan gum: 10.0% by mass

[0063] (result) When this cream was used by five people for two weeks, the redness of their cheeks was reduced compared to before use.

[0064] [Example 9: Liquid Foundation (O / W type)] The liquid foundation was prepared using the following method. (Manufacturing method) A. The following components (1) to (7) were heated and dissolved. The following ingredients (8) to (11) were added to BA, mixed uniformly, and kept at 70°C. C. The following components (12) to (16) were heated and dissolved, and the temperature was maintained at 70°C. Add B to DC and emulsify. After cooling the ED, the following component (17) was added and mixed to obtain a liquid foundation (O / W type).

[0065] (1) Stearic acid: 2.0% by mass (2) Behenyl alcohol: 0.5% by mass (3) Cetanol: 1.0% by mass (4) α-olefin oligomer: 2.0% by mass (5) Cetyl 2-ethylhexanoate: 5.0% by mass (6) Self-emulsifying glyceryl monostearate: 1.0% by mass (7) Methylparaben: 0.2% by mass (8) Titanium oxide: 5.0% by mass (9) Colored pigment: 4.0% by mass (10) Mica: 2.0% by mass (11) Talc: 4.0% by mass (12) Carboxymethylcellulose: 0.2% by mass (13) Xanthan gum: 0.3% by mass (14) Edelweiss extract: 0.05% by mass (15) 1,3-Butylene glycol: 12.0% by mass (16) Purified water: remaining amount (17) Fragrance: 0.2% by mass

[0066] (result) When five people used this liquid foundation continuously for two weeks, the redness on their cheeks was reduced compared to before use.

[0067] [Example 10: Quasi-drug lotion] A quasi-drug lotion was prepared using the following manufacturing method. (Manufacturing method) A. The following components (1) to (4) were mixed and dissolved. B. The following components (5) to (10) were mixed and dissolved. A was added to CB and mixed to obtain a quasi-drug lotion.

[0068] (1) Sorbitan sesquioleate: 0.7% by mass (2) Polyoxyethylene hydrogenated castor oil: 0.3% by mass (3) Ethanol: 10.0% by mass (4) Fragrance: 0.15% by mass (5) Purified water: remaining amount (6) 1,3-Butylene glycol: 8.0% by mass (7) Witch hazel extract: 2.0% by mass (8) Coix seed extract: 0.2% by mass (9) Edelweiss extract: 0.1% by mass (10) Dipotassium glycyrrhizinate: 0.1% by mass

[0069] (result) When five people used this lotion continuously for two weeks, the redness on their cheeks was reduced compared to before use.

[0070] [Example 11: Quasi-drug beauty serum] A quasi-drug beauty serum was prepared using the following manufacturing method. (Manufacturing method) A: The following components (1) to (3) were uniformly dissolved and mixed at 70°C. B: The following components (4) to (12) were uniformly dissolved and mixed at 80°C. C: Add B to A and emulsify at 70°C. After cooling D:C to 40°C, add and mix the following components (13) to (14). The following pre-mixed ingredients (15) to (22) were added to E:D to obtain a quasi-drug beauty serum.

[0071] (1) 1,3-Butylene glycol: 5.0% by mass (2) Tripropylene glycol: 3.0% by mass (3) Purified water: remaining amount (4) Polyoxyethylene sorbitan monooleate (20 E.O.): 0.1% by mass (5) Polyethylene glycol monostearate (55 E.O.): 0.25% by mass (6) Macadamia nut oil fatty acid phytosteryl: 2.0% by mass (7) Light liquid isoparaffin: 3.0% by mass (8) Dimethylpolysiloxane (6CS): 3.0% by mass (9) Cholesterol: 0.1% by mass (10) Tocopherol: 0.01% by mass (11) Cetostearyl alcohol: 0.5% by mass (12) Phenoxyethanol: 0.3% by mass (13) Xanthan gum: 0.15% by mass (14) (Sodium Acrylate / Sodium Acryloyldimethyl Taurate) Copolymer: 0.1% by mass (15) Edelweiss extract: 0.1% by mass (17) Collagen: 0.1% by mass (18) Elastin: 0.1% by mass (19) Hyaluronic acid: 0.1% by mass (20) Kojic acid: 0.5% by mass (21) Ethanol: 4.0% by mass (22) Fragrance: 0.05% by mass

[0072] (result) When five people used this serum continuously for two weeks, the redness in their cheeks was reduced compared to before use.

[0073] [Example 12: Facial Cleansing Foam] The facial cleansing foam was prepared using the following method. (Manufacturing method) A. The following components (1) to (7) were heated and dissolved at 75°C. Dissolved (8) to (9) were added to BA and mixed uniformly. The following ingredients (10) to (15) were added to CB and mixed to obtain a facial cleansing foam.

[0074] (1) Lauric acid: 5.0% by mass (2) Myristic acid: 20.0% by mass (3) Stearic acid: 7.0% by mass (4) Glycerin: 14.0% by mass (5) Polyethylene glycol 1500: 5.0% by mass (6) Lipophilic glyceryl monostearate: 0.8% by mass (7) Ethylene glycol distearate: 1.5% by mass (8) Potassium hydroxide: 6.2% by mass (9) Purified water: remaining amount (10) Potassium N-coconut oil fatty acid acylglycine solution: 7.0% by mass (11) Polyoxyethylene lauryl ether (7E.O.): 3.0% by mass (12) Edelweiss extract: 0.3% by mass (13) Caprylhydroxamic acid: 0.05% by mass (14) Polyquaternium-39: 0.2% by mass (15) Purified water: 5.0% by mass

[0075] (result) When five people used this facial cleanser for two weeks, the redness on their cheeks was reduced compared to before use.

[0076] [Example 13: Cleansing Milk] The cleansing milk was prepared using the following method. (Manufacturing method) A. The following components (1) to (5) were heated and dissolved at 85°C. The heated and dissolved (6) to (7) were added to BA to neutralize it, then it was mixed uniformly and maintained at 75°C. (8) to (15), which were homogeneously mixed at 75°C, were added to CB and emulsified, then cooled to 40°C. (16) to (20) were added to D.C and mixed to obtain cleansing milk.

[0077] (1) Acrylates / C10-30 Alkyl Acrylate Crosspolymer: 0.3% by mass (2) Purified water: 30.0% by mass (3) Disodium edetate: 0.05% by mass (4) Glycerin: 1.0% by mass (5) 1,3-Butylene glycol: 7.0% by mass (6) Triethanolamine: 0.3% by mass (7) Purified water: 9.0% by mass (8) Liquid paraffin: 4.5% by mass (9) Cetyl 2-ethylhexanoate: 17.0% by mass (10) Isopropyl myristate: 4.5% by mass (11) Methylpolysiloxane: 1.0% by mass (12) Hydrogenated polyisobutene: 3.0% by mass (13) Behenyl alcohol: 0.2% by mass (14) Methylparaben: 0.2% by mass (15) Phenoxyethanol: 0.5% by mass (16) Xanthan gum: 0.2% by mass (17) Purified water: remaining amount (18) Polyoxyethylene coconut oil fatty acid monoethanolamide: 0.5% by mass (19) Edelweiss extract: 0.05% by mass (20) Hydroxyacetophenone: 0.02% by mass

[0078] (result) When five people used this cleansing milk for two weeks, the redness on their cheeks was reduced compared to before use.

[0079] [Example 14: Ointment] The ointment was prepared using the following method. (Manufacturing method) A. The following components (1) to (6) were uniformly dissolved at 75°C. B. The following components (7) to (12) were uniformly dissolved at 75°C. B was gradually added to CA, emulsified at 75°C, and cooled to room temperature to obtain an ointment.

[0080] (1) Stearic acid: 18.0% by mass (2) Sorbitan sesquioleate: 1.5% by mass (3) Cetanol: 5.0% by mass (4) Vaseline: 30.0% by mass (5) Tocopherol: 0.01% by mass (6) Methylparaben: 0.2% (7) Triethanolamine: 2.0% by mass (8) Glycerin: 10.0% by mass (9) 1,3-Butylene glycol: 5.0% by mass (10) Ethylhexylglycerin: 0.05% by mass (11) Edelweiss extract: 1.0% by mass (12) Purified water: remaining amount

[0081] (result) When this ointment was used continuously for two weeks on five subjects, the redness of their cheeks was reduced compared to before use.

[0082] [Example 15: Tablet] The tablets were prepared using the following method. (Manufacturing method) A. The following ingredients (1) to (7) were uniformly mixed, and tablets were obtained according to a conventional method.

[0083] (1) Lactose: 24.0% by mass (2) Crystalline cellulose: 20.0% by mass (3) Corn starch: 15.0% by mass (4) Edelweiss extract: 0.2% by mass (5) Glycerin fatty acid ester: 5.0% by mass (6) Silicon dioxide: 1.0% by mass (7) Dextrin: Remaining amount

[0084] [Example 16: Soft drink] The soft drink was prepared using the following method. (Manufacturing method) A. The following ingredients (1) to (5) were uniformly mixed, and a soft drink was obtained according to a conventional method.

[0085] (1) Fructose-glucose solution: 30.0% by mass (2) Emulsifier: 0.5% by mass (3) Edelweiss extract: 0.05% by mass (4) Fragrance: 0.01% by mass (5) Purified water: remaining amount

Claims

1. A lipase production inhibitor containing an extract of edelweiss (Leontopodium alpinum) as its active ingredient, which suppresses lipase production by lipase-producing bacteria.

2. The lipase production inhibitor according to claim 1, wherein the lipase-producing bacteria are commensal skin bacteria.

3. The lipase production inhibitor according to claim 2, wherein the skin commensal bacteria is Propionibacterium acnes.

4. The lipase production inhibitor according to claim 1, which maintains the survival rate of the lipase-producing bacteria at 60% or more.

5. An agent containing an extract of edelweiss (Leontopodium alpinum) as the active ingredient, which prevents and / or improves lipase-related problems.

6. The preventive and / or corrective agent according to claim 5, wherein the problem caused by the lipase is a skin problem.

7. The preventive and / or corrective agent according to claim 6, wherein the skin problem is acne.

8. A cosmetic, pharmaceutical, quasi-drug, or food or beverage containing a lipase production inhibitor according to any one of claims 1 to 4, or a preventive and / or ameliorative agent according to any one of claims 5 to 7.

9. A method for inhibiting lipase production by lipase-producing bacteria, comprising the step of applying and / or ingesting an extract of edelweiss (Leontopodium alpinum).

Images